Lilly Xigris Sepsis Benefit Defended By FDA In NEJM 

30 Sep 2002
News

The Pink Sheet pinkeditor@informa.com

Executive Summary

An FDA analysis of Xigris PROWESS trial data suggests that Lilly's tightening of patient exclusion criteria during the study does not account for greater drug benefit seen after the protocol change

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS040548

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS040548

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Lilly Xigris Sepsis Benefit Defended By FDA In NEJM&nbsp;

News

Executive Summary

Related Content

Generic Biologics: Xigris Approval Suggests Precedent For FDA, GPhA Says

Generic Biologics: Xigris Approval Suggests Precedent For FDA, GPhA Says

Lilly Xigris Marketing Plans Stress Journal Articles, “Sharpened” Messages

Lilly Xigris Marketing Plans Stress Journal Articles, “Sharpened” Messages

Lilly Xigris Price Is $6,800 Per Dose; Sepsis Agent Clears FDA

Lilly Xigris Label Could Exclude Lower-Risk And Sickest Sepsis Patients

Lilly Xigris Label Could Exclude Lower-Risk And Sickest Sepsis Patients

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert

Lilly Xigris Sepsis Benefit Defended By FDA In NEJM